69f73cc3_anderbilt_Ingram_Cancer_Center__Trial_Type
[Protocol No. & Open Date] VICCMD1188 06/08/2012 [Summary] An Open-Label, Phase II Study of Vemurafenib in Patients with BRAF V600 Mutation-Positive Cancers [Trial Type] 
Treatment Adrenocortical Bladder Breast Cervical Colon Dermatologic Esophageal GIST Gastric/Gastroesophageal Gynecologic Head/Neck Kidney (Renal Cell) Liver Lung Multiple Myeloma Neuroendocrine Non Small Cell Ovarian Pancreatic Prostate Rectal Sarcoma Uterine
Urologic / Genitourinary Cancers - Vanderbilt-Ingram Cancer Center
Trial Type